ES3055983T3 - Pegylation of fgf21 - Google Patents

Pegylation of fgf21

Info

Publication number
ES3055983T3
ES3055983T3 ES20189107T ES20189107T ES3055983T3 ES 3055983 T3 ES3055983 T3 ES 3055983T3 ES 20189107 T ES20189107 T ES 20189107T ES 20189107 T ES20189107 T ES 20189107T ES 3055983 T3 ES3055983 T3 ES 3055983T3
Authority
ES
Spain
Prior art keywords
peg
reaction
pegylation
equiv
additive system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20189107T
Other languages
English (en)
Spanish (es)
Inventor
Matthew R Hickey
Antonio Ramirez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES3055983T3 publication Critical patent/ES3055983T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/64Relaxins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES20189107T 2015-11-23 2016-11-22 Pegylation of fgf21 Active ES3055983T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562258644P 2015-11-23 2015-11-23

Publications (1)

Publication Number Publication Date
ES3055983T3 true ES3055983T3 (en) 2026-02-17

Family

ID=57589163

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20189107T Active ES3055983T3 (en) 2015-11-23 2016-11-22 Pegylation of fgf21
ES16816042T Active ES2827776T3 (es) 2015-11-23 2016-11-22 Sistemas de aditivos para uso en la PEGilación de proteínas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16816042T Active ES2827776T3 (es) 2015-11-23 2016-11-22 Sistemas de aditivos para uso en la PEGilación de proteínas

Country Status (17)

Country Link
US (3) US10617765B2 (https=)
EP (2) EP3789395B1 (https=)
JP (2) JP6921821B2 (https=)
KR (1) KR102688003B1 (https=)
CN (2) CN115819494A (https=)
CY (1) CY1123699T1 (https=)
DK (1) DK3380487T3 (https=)
ES (2) ES3055983T3 (https=)
HR (1) HRP20201832T1 (https=)
HU (1) HUE052634T2 (https=)
LT (1) LT3380487T (https=)
PL (1) PL3380487T3 (https=)
PT (1) PT3380487T (https=)
RS (1) RS61072B1 (https=)
SI (1) SI3380487T1 (https=)
SM (1) SMT202000649T1 (https=)
WO (1) WO2017091568A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3380487T (pt) * 2015-11-23 2020-10-29 Bristol Myers Squibb Co Sistemas de aditivos para utilização na peguilação de proteínas
HRP20240016T1 (hr) * 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
CN111484551B (zh) * 2020-03-19 2022-02-11 北京翼方生物科技有限责任公司 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
US7329516B2 (en) * 2004-03-17 2008-02-12 Anticancer, Inc. Methods for increasing protein polyethylene glycol (PEG) conjugation
US20060286657A1 (en) * 2005-06-01 2006-12-21 Samuel Zalipsky Novel bioconjugation reactions for acylating polyethylene glycol reagents
CN104710503B (zh) * 2005-11-08 2023-04-25 Ambrx 公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
CA2682147C (en) * 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
AU2014212308B2 (en) 2013-01-30 2018-08-09 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
WO2014176284A1 (en) 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
PT3380487T (pt) * 2015-11-23 2020-10-29 Bristol Myers Squibb Co Sistemas de aditivos para utilização na peguilação de proteínas

Also Published As

Publication number Publication date
ES2827776T3 (es) 2021-05-24
EP3789395A1 (en) 2021-03-10
JP7257457B2 (ja) 2023-04-13
RS61072B1 (sr) 2020-12-31
PT3380487T (pt) 2020-10-29
US11213589B2 (en) 2022-01-04
SI3380487T1 (sl) 2020-11-30
HRP20201832T1 (hr) 2021-01-08
LT3380487T (lt) 2020-12-28
WO2017091568A1 (en) 2017-06-01
US20190351065A1 (en) 2019-11-21
CN108350025B (zh) 2023-02-21
US20220160883A1 (en) 2022-05-26
WO2017091568A8 (en) 2018-01-04
EP3380487A1 (en) 2018-10-03
JP2019503994A (ja) 2019-02-14
PL3380487T3 (pl) 2020-12-28
HUE052634T2 (hu) 2021-05-28
EP3380487B1 (en) 2020-09-02
US20200276319A1 (en) 2020-09-03
CY1123699T1 (el) 2022-03-24
JP6921821B2 (ja) 2021-08-18
CN115819494A (zh) 2023-03-21
EP3789395B1 (en) 2025-08-27
US10617765B2 (en) 2020-04-14
JP2021176890A (ja) 2021-11-11
KR20180081610A (ko) 2018-07-16
SMT202000649T1 (it) 2021-01-05
CN108350025A (zh) 2018-07-31
KR102688003B1 (ko) 2024-07-23
DK3380487T3 (da) 2020-12-07

Similar Documents

Publication Publication Date Title
ES3055983T3 (en) Pegylation of fgf21
US20230295221A1 (en) Efficient peptide condensation method for difficult sequences
CA2918064A1 (en) Amino acid derivatives
CA3095071A1 (en) Non-natural amatoxin-type antibody conjugate
Guthrie et al. Ketoxime peptide ligations: oxidative couplings of alkoxyamines to N-aryl peptides
Dahiya et al. Toward the synthesis and pharmacological screening of a natural cycloheptapeptide of plant origin
Arndt et al. Solution phase synthesis and purification of the minigramicidin ion channels and a succinyl-linked gramicidin
TW202330571A (zh) 具有光裂解部位的化合物、連結物及使用此的篩選方法
US9850469B2 (en) Methods of stapling and unstapling peptides and proteins
Yang et al. Carbon dioxide enhances sulphur-selective conjugate addition reactions
Hughes Amino Acids, Peptides and Proteins in Organic Chemistry, Protection Reactions, Medicinal Chemistry, Combinatorial Synthesis
US11053279B2 (en) Methods for the site-selective coupling of a first agent to a second agent
KR101692992B1 (ko) 고리형 펩타이드의 사전 활성화 합성방법 및 이에 따라 합성된 고리형 펩타이드
Islam Cyclization-Based Site-Selective N-Terminal Cysteine Conjugation, Peptide Stapling and Histone Deacetylase (HDAC) Probing
HK40104266A (zh) 具有光开裂性部位的化合物、连结体和应用其的筛选方法
Kang Native chemical thioesterification: synthesis of peptide and protein thioesters through an N→ S acyl shift
ES2367843T3 (es) Tecnología de lantionina ortogonal protegida de forma diferencial.
Misicka 12 General Strategies of Peptide Synthesis
Postma Novel Disulfide Formation Strategies in Peptide Synthesis
Méret Development of an efficient and flexible method for the solid-phase synthesis of N-hydroxypolyamine derivatives
EA023323B1 (ru) Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона